
We Develop Pan Coronavirus Antivirals
HALO'S PROPRIETARY FREE FATTY ACID FORMULA IS A PAN CORONAVIRUS ANTIVIRAL
The pocket and antiviral mechanism we discovered are fully conserved in:
- SARS1 (2003), MERS (2012) and SARS-CoV-2 (2019)
- all Variants of Concern (VOC) alpha, beta, delta, omicron

OUR PIPELINE & SCIENCE
INVESTMENT, LICENSING, AND PARTNERING
Halo Therapeutics is backed by experienced institutional and private investors. Key investors include the Development Bank of Wales, the KBA group and Science Angels Syndicate.
The Development Bank of Wales is a Welsh development bank that provides financial support for Welsh businesses and is owned by the Welsh Government. The bank provides loans for businesses to start up, strengthen and grow and also provides equity investments for already established businesses.
The KBA Group is an angel consortium of high net worth individuals co-led by Dr Nikolaos Kostopoulos and Paras Barot.
Science Angel Syndicate is a community of entrepreneurs and investors who source world class scientific discoveries that impact society on a global scale.
Please contact us for partnering, licensing, or investment opportunities in pan coronavirus antivirals and potential antiviral drugs for Covid-19.
Our Company
Halo Executive Team

Prof. Adam Finn
- Head clinician in UK wide RECOVERY trial ongoing for COVID-19
- Designing our Clinical Trials
- Expert in viral transmission New York Times Article by Adam
NEWS

On 1st July 2023
KEY PUBLICATIONS
Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy
The free fatty acid–binding pocket is a conserved hallmark in pathogenic β-coronavirus spike proteins from SARS-CoV to Omicron
Pathogen-sugar interactions revealed by universal saturation transfer analysis
Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein
Oskar Staufer, Kapil Gupta, Jochen Estebano Hernandez Bücher, Fabian Kohler, Christian Sigl, Gunjita Singh, Kate Vasileiou, Ana Yagüe Relimpio, Meline Macher, Sebastian Fabritz, Hendrik Dietz, Elisabetta Ada Cavalcanti Adam, Christiane Schaffitzel, Alessia Ruggieri, Ilia Platzman, Imre Berger & Joachim P. Spatz
Structural insights in cell-type specific evolution of intra-host diversity by SARS-CoV-2
The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour.
The SARS-CoV-2 spike protein: balancing stability and infectivity
Imre Berger, Christiane Schaffitzel
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Contact Us
Halo Therapeutics
- Britannia House, Caerphilly Business Park, Van Road, Caerphilly, CF83 3GG Wales
- +44 117 403 4035
- contact@halo-therapeutics.com